

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

Nile Therapeutics

Form: 8-K

Date Filed: 2007-10-19

Corporate Issuer CIK: 1133869

Symbol: NLTX

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): October 16, 2007

NILE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

333-55166
(Commission
File Number)

88-0363465
(I.R.S. Employer
Identification No.)

**2850 Telegraph Avenue Suite #310
Berkeley, CA 94705**
(Address of Principal Executive Offices)

(510) 281-7700
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 16, 2007, the Board of Directors (the "Board") of Nile Therapeutics, Inc. appointed Pedro Granadillo as a member of the Board. The full text of the press release issued in connection with the appointment of Mr. Granadillo as a member of the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Nile Therapeutics, Inc. dated October 18, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: October 19, 2007

NILE THERAPEUTICS, INC.

By: /s/ Peter M. Strumph

Name: Peter M. Strumph

Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press Release of Nile Therapeutics, Inc. dated October 18, 2007.

Nile Therapeutics Appoints Pedro Granadillo to Board of Directors

BERKELEY, Calif., Oct. 18, 2007 /PRNewswire-FirstCall/ – Nile Therapeutics, Inc. (OTCBB: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, announced today that Mr. Pedro Granadillo was appointed on October 16, 2007 to serve on its board of directors. Mr. Granadillo is a highly-respected pharmaceutical industry leader with over 30 years of experience in corporate management, human resources, manufacturing and quality assurance.

“We are pleased to welcome such a widely respected and experienced senior pharmaceutical executive to our Board of Directors,” said Peter Strumph, Chief Executive Officer of Nile. “Pedro brings to Nile more than three decades of industry knowledge and extensive pharmaceutical development and management experience. As we continue to drive our programs forward, it is imperative that we leverage the strategic guidance of leaders like Pedro who have a proven track record in drug development, corporate strategy and building effective teams and infrastructure.”

Mr. Granadillo served as Senior Vice President for Eli Lilly and Company (“Lilly”) until 2004 when he retired after 34 years of service. He was a member of Lilly’s Policy Committee, which was comprised of its top seven executives. As Lilly’s top human resources, manufacturing and quality executive, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as, a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly’s conventional “small-molecule” pharmaceuticals and “large-molecule” biotech therapies.

“I am honored to join Nile’s board of directors,” said Mr. Granadillo. “I look forward to working with the entire Nile management team as they move its pre-clinical and clinical pipeline forward and advance the company’s strategic business objectives.”

Mr. Granadillo is currently a member of the boards of directors of First Indiana Bank, Indianapolis, IN; Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Purdue University Research Foundation. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company’s strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at www.nilethera.com.

Contact:

Daron Evans
Chief Financial Officer
Nile Therapeutics, Inc.
510-281-7700
info@nilethera.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile’s product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or

events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Form 8-K filed with the Securities and Exchange Commission on September 21, 2007. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Source: Nile Therapeutics, Inc.

CONTACT: Daron Evans, Chief Financial Officer, Nile Therapeutics, Inc.,
+1-510-281-7700, info@nilethera.com

Web site: <http://www.nilethera.com/>